EN-374
X-linked Chronic Granulomatous Disease (X-CGD)
Pre-clinical / CTA ClearedActive
Key Facts
Indication
X-linked Chronic Granulomatous Disease (X-CGD)
Phase
Pre-clinical / CTA Cleared
Status
Active
Company
About Ensoma
Ensoma is a private, pre-clinical stage biotech developing a novel in vivo platform for engineering hematopoietic stem cells (HSCs). Its technology aims to supersede complex ex vivo cell therapies by delivering genetic tools directly to a patient's HSCs, enabling durable, off-the-shelf treatments for genetic, hematologic, and oncologic diseases. The company is advancing lead programs in X-linked chronic granulomatous disease (X-CGD), sickle cell disease, and solid tumors, supported by top-tier investors. Ensoma's approach promises to simplify the patient treatment journey and scale manufacturing to serve large global populations.
View full company profile